[123I]Iomazenil SPECT benzodiazepine receptor imaging in schizophrenia

Psychiatry Research - Neuroimaging

Volumn 91, Issue 3, 1999, Pages 163-173

  Verhoeff, Nicolaas Paul L G ^a   Soares, Jair C ^a   D'Souza, Cyril D ^a   Gil, Roberto ^b   Degen, Kathleen ^a   Abi Dargham, Anissa ^b   Zoghbi, Sami S ^a   Fujita, Masahiro ^a   Rajeevan, Nallakkandi ^a   Seibyl, John P ^c   Krystal, John H ^a   Van Dyck, Christopher H ^a   Charney, Dennis S ^a   Innis, Robert B ^a,c  

^a YALE UNIVERSITY   (United States)

^b Columbia Univ Coll Phys Surgs ^*  (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

GABA; Negative symptoms; Positive symptoms; Psychosis; Thought disorganization

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; BENZODIAZEPINE RECEPTOR; IODINE 123; IOMAZENIL; DIAGNOSTIC AGENT; DRUG DERIVATIVE; FLUMAZENIL; RADIOACTIVE IODINE;

ADULT; ARTICLE; CIGARETTE SMOKING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IN VIVO STUDY; MALE; PATHOPHYSIOLOGY; PREFRONTAL CORTEX; PRIORITY JOURNAL; PSYCHOSIS; RECEPTOR DENSITY; SCHIZOPHRENIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYMPTOMATOLOGY; THOUGHT DISORDER; BRAIN; BRAIN CORTEX; BRAIN MAPPING; FEMALE; FRONTAL LOBE; HEMISPHERIC DOMINANCE; MIDDLE AGED; PHYSIOLOGY; PSYCHOLOGICAL RATING SCALE; SCINTISCANNING;

ADULT; BRAIN; BRAIN MAPPING; CEREBRAL CORTEX; DOMINANCE, CEREBRAL; FEMALE; FLUMAZENIL; FRONTAL LOBE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; RECEPTORS, GABA-A; SCHIZOPHRENIA; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0033547064     PISSN: 09254927     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0925-4927(99)00027-X     Document Type: Article

References (60)

1. 123I]iomazenil: kinetic and equilibrium paradigms. Journal of Nuclear Medicine. 35:1994;228-238.
2. 123I]iomazenil. American Journal of Psychiatry. 155:1998;1550-1555.
3. Abi-Dargham A., Laruelle M., Krystal J., D'Souza C., Zoghbi S., Baldwin R.M., Seibyl J., De Erasquin G., Charney D., Innis R.B. No evidence of altered in vivo benzodiazepine receptor binding in schizophrenia. Neuropsychopharmacology. 20:1999;650-661.
4. Akbarian S., Huntsman M.M., Kim J.J., Tafazzoli A., Potkin S.G., Bunney W. Jr., Jones E.G. GABAA receptor subunit gene expression in human prefrontal cortex: comparison of schizophrenics and control subjects. Cerebral Cortex. 5:1995;550-560.
5. Akbarian S., Kim J.J., Potkin S.G., Hagman J.O., Tafazzoli A., Bunney W. Jr., Jones E.G. Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Archives of General Psychiatry. 52:1995;258-266.
6. 123I-iomazenil SPET study. Biological Psychiatry. 43:1998;107-117.
7. Battaglia J., Moss S., Rush J., Kang J., Mendoza R., Leedom L., Dubin W., McGlynn C., Goodman L. Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. American Journal of Emergency Medicine. 15:1997;335-340.
8. Beasly C.L., Reynolds G.P. Parvalbumin-immunoreactive neurons are reduced in the prefrontal cortex of schizophrenics. Schizophrenia Research. 24:1997;349-355.
9. Beer H.F., Blauenstein P.A., Hasler P.H., Delaloye B., Riccabona G., Bangerl I., Hunkeler W., Bonetti E.P., Pieri L., Richards J.G., Schubiger P.A. In vitro and in vivo evaluation of iodine-123 Ro 16-0154: a new imaging agent for SPECT investigations of benzodiazepine receptors. Journal of Nuclear Medicine. 31:1990;1007-1014.
10. Benes F.M., McSparren J., Bird E.D., Vincent S.L., SanGiovani J.P. Deficits in small interneurons in schizophrenic cortex. Archives of General Psychiatry. 48:1991;996-1001.
11. Benes F.M., Vincent S.L., Alsterberg G., Bird E.D., SanGiovanni J.P. Increased GABAa receptor binding in superficial layers of cingulate cortex in schizophrenics. Journal of Neuroscience. 12:1992;924-929.
12. Benes F.M., Khan Y., Vincent S.L., Wickramasinghe R. Differences in the subregional and cellular distribution of GABAA receptor binding in the hippocampal formation of the human brain. Synapse. 22:1996;338-349.
13. Benes F.M., Wickramasinghe R., Vincent S.L., Khan Y., Todtenkopf M. Uncoupling of GABAA and benzodiazepine receptor binding activity in the hippocampal formation of schizophrenic brain. Brain Research. 755:1997;121-129.
14. Bennett J.P., Enna S.J., Bylund D.B., Gillin J.C., Wyatt R.J., Snyder S.H. Neurotransmitter receptors in fronal cortex of schizophrenics. Archives of General Psychiatry. 36:1979;927-934.
15. Bird E.D., Spokes E.G., Barnes J., MacKay A.V., Iversen L.L., Shepherd M. Increased brain dopamine and reduced glutamic acid decarboxylase and choline acetyl transferase activity in schizophrenia and related psychoses. Lancet. 2:1977;1157-1158.
16. Bryson G., Bell M., Greig T., Kaplan E. Internal consistency, temporal stability and neuropsychological correlates of three cognitive components of the Positive and Negative Syndrome Scale (PANSS). Schizophrenia Research. 38:1999;27-35.
17. Busatto G.F., Pilowsky L.S., Costa D.C., Ell P.J., David A.S., Lucey J.V., Kerwin R.W. Correlation between reduced in vivo benzodiazepine receptor binding and severity of psychotic symptoms in schizophrenia. American Journal of Psychiatry. 154:1997;56-63.
18. Carpenter W.T., Buchanan R.W., Kirkpatrick B., Breier A.F. Diazepam treatment of early signs of exacerbation in schizophrenia. American Journal of Psychiatry. 156:1999;299-303.
19. Cross A.J., Crow T.J., Owen F. Gamma-aminobutyric acid in the brain in schizophrenia (letter). Lancet. 1:1979;560-561.
20. Friston K.J., Ashburner J., Poline J.B., Frith C.D., Heather J.D., Frackowiak R.S.L. Spatial registration and normalisation of images. Human Brain Mapping. 2:1995;165-189.
21. Fujita M., Woods S.W., Verhoeff N.P.L.G., Abi-Dargham A., Baldwin R.M., Zoghbi S.S., Soares J.C., Jatlow P.A., Krystal J.H., Rajeevan N., Charney D.S., Seibyl J.P., Innis R.B. Changes of benzodiazepine receptors during chronic benzodiazepine administration in humans. Eur J Pharmacol. 368:1999;161-172.
22. Gavish M., Weiszmann R., Becker D., Tanne Z. Effect of chronic haloperidol treatment on peripheral benzodiazepine binding sites in cerebral cortex of rats. Journal of Neural Transmission. 74:1988;109-116.
23. Giardino L., Calza L., Piazza P.V., Amato G. Multiple neurochemical actions of clozapine: a quantitative autoradiographic study of DA2, opiate and benzodiazepine receptors in the rat brain after long-term treatment. Journal of Neural Transmission General Section. 83:1991;189-203.
24. 3H]muscimol binding sites increased in autopsied brains of chronic schizophrenics. Life Sciences. 40:1987;259-266.
25. Heiss W.D., Grond M., Thiel A., Ghaemi M., Sobesky J., Rudolf J., Bauer B., Wienhard K. Permanent cortical damage detected by flumazenil positron emission tomography in acute stroke. Stroke. 29:1998;454-461.
26. Jueptner M., Weiller C. Does measurement of regional cerebral blood flow reflect synaptic activity? - implications for PET and fMRI. NeuroImage. 2:1995;148-156.
27. Kahn J.P., Puertollano M.A., Schane M.D., Klein D.F. Adjunctive alprazolam for schizophrenia with panic anxiety: clinical observation and pathogenetic implications. American Journal of Psychiatry. 145:1988;742-744.
28. Kay, S.R., Opler, L.A., Fiszbein, A., 1992. The Positive and Negative Syndrome Scale (PANSS) Manual. Multi-Health Systems, Inc., Toronto, ON, Canada.
29. 3H]gamma-aminobutyric acid in the substantia nigra and in the globus pallidus of the rat. Brain Research. 649:1994;129-135.
30. Kiuchi Y., Kobayashi T., Takeuchi J., Shimizu H., Ogata H., Toru M. Benzodiazepine receptors increase in postmortem brain of chronic schizophrenics. European Archives of Psychiatric and Neurological Sciences. 239:1989;71-78.
31. 123I]iomazenil binding to benzodiazepine receptors in non-human primates: II. Equilibrium analysis of constant infusion experiments and correlation with in vitro parameters. Journal of Cerebral Blood Flow and Metabolism. 14:1994;453-465.
32. 123I-iomazenil. VIIIth Biennial Winter workshop on schizophrenia. Schizophrenia Research 18, 199 (Abstract).
33. Lawrie S.M., Abukmeil S.S. Brain abnormality in schizophrenia. A systematic and quantitative review of volumetric magnetic resonance imaging studies. British Journal of Psychiatry. 172:1998;110-120.
34. Leonard S., Adams C., Breese C.R., Adler L.E., Bickford P., Byerly W., Coon H., Griffith J.M., Miller C., Myles-Worsley M., Nagamoto H.T., Rollins Y., Stevens K.E., Waldo M., Freeman R. Nicotinic receptor function in schizophrenia. Schizophrenia Bulletin. 22:1996;431-445.
35. Liddle P.F., Friston K.J., Frith C.D., Hirsch S.R., Jones T., Frackowiak R.S.J. Patterns of cerebral blood flow in schizophrenia. British Journal of Psychiatry. 160:1992;179-186.
36. 3H]aminobutyric acid in rabbit caudate nucleus slices. Journal of Neurochemistry. 46:1986;1109-1117.
37. 3H]flumazenil in deafferented visual areas of the adult mouse brain. Synapse. 18:1993;79-85.
38. Onishi Y., Yonekura Y., Tanaka F., Nishizawa S., Okazawa H., Ishizu K., Fujita T., Konishi J., Mukai T. Delayed image of iodine-123 iomazenil as a relative map of benzodiazepine receptor binding: the optimal scan time. European Journal of Nuclear Medicine. 23:1996;1491-1497.
39. Pandey G.N., Conley R.R., Pandey S.C., Goel S., Roberts R.C., Tamminga C.A., Chute D., Smialek J. Benzodiazepine receptors in the postmortem brain of suicide victims and schizophrenic subjects. Psychiatry Research. 71:1997;137-149.
40. Perry T.L., Buchanan J., Kish S., Hanssen S. Gamma-aminobutyric acid deficiency in brain of schizophrenic patients. Lancet. 1:1979;237-239.
41. Rajeevan N., Zubal I.G., Ramsby S.Q., Zoghbi S.S., Seibyl J.P., Innis R.B. Significance of non-uniform attenuation correction in quantitative brain SPECT imaging. Journal of Nuclear Medicine. 39:1998;1719-1726.
42. Reynolds G.P., Stroud D. Hippocampal benzodiazepine receptors in schizophrenia. Journal of Neural Transmission General Section. 93:1993;151-155.
43. Reynolds G.P., Czudek C., Andrews H.B. Deficit and hemispheric asymmetry. Biological Psychiatry. 27:1990;1038-1044.
44. Schröder J., Bubeck B., Demisch S., Sauer H. Benzodiazepine receptor distribution and diazepam binding in schizophrenia: an exploratory study. Psychiatry Research: Neuroimaging. 68:1997;125-131.
45. Sherman A.D., Davidson A.T., Baruah S., Hegwood T.S., Waziri R. Evidence of glutamatergic deficiency in schizophrenia. Neuroscience Letters. 121:1991;77-80.
46. Simpson M.D., Slater P., Deakin J.F.W., Royston M.C., Skan W.J. Reduced GABA uptake sites in the temporal lobe in schizophrenia. Neuroscience Letters. 107:1989;211-215.
47. Simpson M.D.C., Slater P., Royston M.C., Deakin J.F.W. Regionally selective deficits in uptake sites for glutamate and gamma-aminobutyric-acid in the basal ganglia in schizophrenia. Psychiatry Research. 42:1992;273-282.
48. 3H]flunitrazepam binding in cingulate cortex and hippocampus of postmortem schizophrenic brains: is selective loss of glutamatergic neurons associated with major psychoses? Neurochemical Research. 18:1993;219-223.
49. 11C]Ro 15-4513. Neuroscience Letters. 159:1993;207-210.
50. Sullivan E.V., Lim K.O., Mathalon D., Marsh L., Beal D.M., Harris D., Hoff A.L., Faustman W.O., Pfefferbaum A. A profile of cortical grey matter volume deficits characteristic of schizophrenia. Cerebral Cortex. 8:1998;117-124.
51. Talairach J., Tournoux P. Co-planar Stereotaxic Atlas of the Human Brain. 3-Dimensional Proportional System: An Approach to Cerebral Imaging. 1988;Thieme Medical Publishers, Inc, New York.
52. Tanaka F., Yonekura Y., Ikeda A., Terada K., Mikuni N., Nishizawa S., Ishizu K., Okazawa H., Hattori N., Shibasaki H., Konishi J., Onishi Y. Presurgical identification of epileptic foci with iodine-123 iomazenil SPET: comparison with brain perfusion SPET and FDG PET. European Journal of Nuclear Medicine. 24:1997;27-36.
53. Verhoeff N.P.L.G., Petroff O.A.C., Hyder F., Zoghbi S.S., Fujita M., Rajeevan N., Rothman D.L., Seibyl J.P., Mattson R.H., Innis R.B. 1Effects of vigabatrin on the GABA-ergic system as determined by [123I]iomazenil SPECT and GABA MRS'. Epilepsia. 40:1999;1433-1438.
54. 11C-Diprenorphine binding in Huntington's disease: a comparison of region of interest analysis with statistical parametric mapping. Journal of Cerebral Blood Flow and Metabolism. 17:1997;943-949.
55. White L., Harvey P.D., Opler L., Lindenmayer J.P., Study Group PANSS Empirical assessment of the factorial structure of clinical symptoms in schizophrenia. A multisite, multimodel evaluation of the factorial structure of the Positive and Negative Syndrome Scale. Psychopathology. 30:1997;263-274.
56. Woo T.U., Miller J.L., Lewis D.A. Schizophrenia and the parvalbumin-containing class of cortical local circuit neurons. American Journal of Psychiatry. 154:1997;1013-1015.
57. Woo T.U., Whitehead R.E., Melchitzky D.S., Lewis D.A. A subclass of prefrontal gamma-aminobutyric acid axon terminals are selectively altered in schizophrenia. Proceedings of the National Academy of Sciences of the United States of America. 95:1998;5341-5346.
58. Wright I.C., Ellison Z.R., Sharma T., Friston K.J., Murray R.M., McGuire P.K. Mapping of grey matter changes in schizophrenia. Schizophrenia Research. 35:1999;1-14.
59. Yurgelun-Todd D.A., Kinney D.K., Sherwood A.R., Renshaw P.F. Magnetic resonance in schizophrenia. Seminars in Clinical Neuropsychiatry. 1:1996;4-19.
60. 123I]iomazenil in human and nonhuman primates. International Journal of Radiation Applications and Instrumentation. Part B, Nuclear Medicine and Biology. 19:1992;881-888.